header-medias

An eminent oncologist joins the GlioCure Scientific and Medical Advisory Board

normal

Dr. Jean-Pierre BIZZARI, world renowned expert in oncology, is joining GlioCure's Scientific and Medical Advisory Board.

Angers, July 6th 2017 - GlioCure SAS, a biotechnology company dedicated to the treatment of glioblastoma, is pleased to announce the appointment of Dr. Jean-Pierre BIZZARI to his Scientific and Medical Advisory Board.

Dr. Jean-Pierre BIZZARI is a member of the Scientific Advisory Board of the National Cancer Institute (INCa), a member of the International Board of MATWIN and Chairman of the New Drug Advisory Committee of the European Organization for Research and Treatment Of Cancer (EORTC). Previously, Dr. BIZZARI was in charge of the clinical development in oncology of major pharmaceutical companies worldwide. He was Executive Vice President and Director of Clinical Development in Oncology (United States, Europe, Asia and Japan) of Celgene from 2008 to 2015. Dr. BIZZARI was involved in the clinical development of several anti-cancer agents Taxotere®, Eloxatin®, Abraxane®, Irinotecan® and Gliadel® Wafer.

At GlioCure's Scientific and Medical Advisory Board, Jean-Pierre BIZZARI joins Dr. Joël EYER, internationally renowned expert on the neuronal cytoskeleton, research director at INSERM and co-founder of GlioCure, and Prof. Marc-Eric HALASTCH, neurosurgeon oncologist at the University Hospital of Ulm in Germany and one of the best European glioblastoma specialist.

The Scientific and Medical Advisory Board is a strategic resource for GlioCure that completes the non-regulatory preclinical development of GC01, its most advanced anti-glioblastoma molecule. "We are delighted with the arrival of Dr. BIZZARI on our Scientific and Medical Advisory Board, which testifies to the quality of the research that GlioCure is producing and the tremendous potential of GC01" said Louis-Marie Bachelot, CEO of GlioCure. "Thanks to his impressive clinical and industrial experience, Dr. BIZZARI will provide us with critical insight in defining our strategy to make GC01 a genuine drug for patients for whom no satisfactory treatment exists today".

About GlioCure :
GlioCure is a spin-off company of Angers and McGill Montreal universities which aims to cure glioblastoma, the most frequent and aggressive brain tumor with about 200,000 deaths a year worldwide. To do this, GlioCure relies on an international team of researchers and clinicians specializing in this pathology and chooses to develop products specific to this indication. Its first product GC01, a new generation anti-mitotic peptide, is at the end of non-regulatory preclinical development.
For more information visit our website: www.gliocure.com

Media and Investors Relation:
Louis-Marie Bachelot, CEO, +33(0)6 14 03 38 26, lm.bachelot@gliocure.com

Download PDF

Retour